STAAR Surgical (NASDAQ:STAA) Receives Average Rating of “Hold” from Analysts

STAAR Surgical (NASDAQ:STAA) has earned a consensus rating of “Hold” from the eight brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $43.33.

Several research firms have recently weighed in on STAA. Stifel Nicolaus decreased their price objective on shares of STAAR Surgical from $50.00 to $44.00 and set a “buy” rating for the company in a report on Monday, August 26th. Canaccord Genuity Group dropped their target price on STAAR Surgical from $41.00 to $31.00 and set a “hold” rating on the stock in a research report on Friday, November 1st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research report on Thursday, October 31st.

STAAR Surgical Stock Performance

Shares of NASDAQ:STAA opened at $26.63 on Friday. The firm has a market capitalization of $1.31 billion, a P/E ratio of 60.52 and a beta of 0.61. The stock has a 50 day moving average price of $30.99 and a 200-day moving average price of $36.81. STAAR Surgical has a 52-week low of $25.88 and a 52-week high of $52.68.

Institutional Trading of STAAR Surgical

A number of institutional investors have recently made changes to their positions in STAA. Arcadia Investment Management Corp MI purchased a new stake in STAAR Surgical in the 3rd quarter worth approximately $37,000. Quarry LP purchased a new position in shares of STAAR Surgical in the 3rd quarter valued at about $50,000. Covestor Ltd raised its holdings in STAAR Surgical by 38.9% in the 1st quarter. Covestor Ltd now owns 2,690 shares of the medical instruments supplier’s stock worth $103,000 after purchasing an additional 754 shares during the period. Quest Partners LLC purchased a new position in STAAR Surgical during the third quarter worth approximately $128,000. Finally, Canada Pension Plan Investment Board acquired a new stake in STAAR Surgical in the second quarter valued at approximately $129,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.